Vicore Pharma Holding AB (STU:6Y4)
€ 0.74 -0.001 (-0.13%) Market Cap: 170.68 Mil Enterprise Value: 147.97 Mil PE Ratio: 0 PB Ratio: 2.28 GF Score: 35/100

Vicore Pharma Holding AB at Redeye Life Science Days Transcript

Nov 11, 2021 / NTS GMT
Release Date Price: €1.66 (-0.35%)
Fredrik Thor
Redeye AB - Analyst

Welcome to Redeye. My name is Fredrik Thor, and today we're going to talk about Vicore Pharma as an investment case. Vicore is a mid-stage clinical biotech company.

It was founded back in 2000, based on research from Uppsala University and Sahlgrenska Academy. It has been on the stock market since 2015. It's a rare-disease company focusing on rare lung disorders, and specifically, fibrotic lung disorders and IPF. And IPF is idiopathic pulmonary fibrosis, which were a rare disease that we're going to talk about a bit later on.

And the company has four programs in total, VP01 to VP04. The lead program is VP01 where we see most potential in our valuation. Stock is now listed on Nasdaq main market. And we can see in terms of share price performance that us with almost all biotech stocks in Sweden at the moment, the sentiment has been very weak. And the stock has traded down quite a bit the last year or so, and it now trades below our bear case.

So we think that most potential discount in stock at this moment. And why do we find Vicore to be an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot